Page 106 of 1,035: studies 1,051 to 1,060 of 10,348, newest first. Back to the depression overview
February 27, 2025 Kristin Raj
Ketamine and esketamine show promise in bipolar depression, with 40% of patients responding to twice-weekly treatment. Full remission occurs in 13%. No immediate manic switches occurred during intensive treatment, but 30% experienced hypomania/mania during maintenance phase. Most episodes were mild. Consider involving family members in monitoring mood changes. Patients with severe mania or...
Scientific Reports February 26, 2025 Merav Catalogna, Ya'Ira Somerville, Nira Saporta et al. 6 citations
Late-life depression represents a significant health concern, linked to disruptions in brain connectivity and immune functioning, mood regulation, and cognitive function. This pilot study explores a digital intervention targeting mental health, brain health, and immune functioning in individuals aged 55-60 with subjective cognitive decline, elevated stress and depressive symptoms. Seventeen...
Journal of Psychopharmacology February 26, 2025 Sara de la Salle, Jennifer L Phillips, Pierre Blier et al. 3 citations
A sub-anesthetic dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces robust antidepressant effects in treatment-resistant major depressive disorder (MDD). The mismatch negativity (MMN) is reliant on glutamatergic neurotransmission and reduced by NMDAR antagonists. The MMN may characterise the neural mechanisms underlying ketamine's effects. This study examined the...
PLoS One February 25, 2025 Jiaxi Wang, Haote Fu, Xiaoling Feng et al.
In this study, we explored whether nightmare distress mediated the correlation between autobiographical memory specificity and depression. 112 participants provided their most recent dreams that happened within one month, and finished some scales that measured depression, autobiographical memory specificity, and nightmare distress. In line with our hypothesis, nightmare distress was the...
Annual Review of Neuroscience February 19, 2025 Macauley Smith Breault, Sirma Orguc, Ohyoon Kwon et al. 13 citations
Major depressive disorder and treatment-resistant depression are significant worldwide health problems that need new therapies. The success of the anesthetic ketamine as an antidepressant is well known. It is less widely known that several other anesthetic agents have also shown antidepressant effects. These include nitrous oxide, propofol, isoflurane, sevoflurane, dexmedetomidine, and xenon....
Schizophrenia Bulletin February 18, 2025 Yujia Zhai
Abstract Background With the arrival of the new era, teenagers face enormous academic and life pressures, which are accompanied by various psychological and physiological problems, and in severe cases, even depression. Depression can affect various aspects of people’s lives and is gradually becoming younger, with teenagers experiencing more severe depression problems. Therefore, it is necessary...
Psychiatric Quarterly February 18, 2025 Zhijian Ma, Fengle Wu, Wen Zheng 4 citations
This meta-analysis aimed to compare the efficacy and safety of ketamine versus electroconvulsive therapy (ECT) in patients with major depressive disorder(MDD). A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases up to November 2024. The randomized controlled trials evaluating the efficacy and safety of ketamine and ECT in MDD patients were...
Cancer cell international February 18, 2025 Jiachi Xu, Mingcan Li, Yu Hu et al. 6 citations
Postoperative depression significantly affects the quality of life of breast cancer patients. This study explores the potential therapeutic effects of esketamine on postoperative depression through modulation of the TREK-1 two-pore domain potassium channel. We analyzed data from 54 female breast cancer patients who underwent surgery at our hospital between 2019 and 2023, dividing them into...
Journal of Education, Health and Sport February 17, 2025 Urszula Kaczmarska, Michał Jakub Cioch, Julia Nowak et al.
Introduction Depression is one of the most common mental illnesses. Over the course of a lifetime, several percent of the adult population suffers from depression. There are many treatments for depression like pharmacotherapy and psychotherapy. In this article, we wanted to focus on the effectiveness of ketamine in treating depression. Aim of study The study aimed to summarize the available...
Neuroscience February 16, 2025 Xinxu Ma, Shanshan Xue, Hongzhe Ma et al. 12 citations
The mechanisms underlying esketamine's therapeutic effects remain elusive. The study aimed to explore the impact of single esketamine treatment on LPS-induced adolescent depressive-like behaviors and the role of Nrf2 regulated neuroinflammatory response in esketamine-produced rapid antidepressant efficacy. Adolescent male C57BL/6J mice were randomly assigned to three groups: control, LPS, and...